Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome

被引：180

作者：

Osterweil, Emily K. ^{[1
]}

Chuang, Shih-Chieh ^{[2
,3
]}

Chubykin, Alexander A. ^{[1
]}

Sidorov, Michael ^{[1
]}

Bianchi, Riccardo ^{[2
,3
]}

Wong, Robert K. S. ^{[2
,3
]}

Bear, Mark F. ^{[1
]}

机构：

[1] MIT, Howard Hughes Med Inst, Picower Inst Learning & Memory, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA

[2] Suny Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Brooklyn, NY 11203 USA

[3] Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA

来源：

NEURON | 2013年 / 77卷 / 02期

关键词：

EPILEPTIFORM DISCHARGES; MENTAL-RETARDATION; EPILEPSY; SUPPRESSION; INDUCTION; MGLUR5; MICE; SEIZURES; STATIN;

D O I：

10.1016/j.neuron.2012.01.034

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Many neuropsychiatric symptoms of fragile X syndrome (FXS) are believed to be a consequence of altered regulation of protein synthesis at synapses. We discovered that lovastatin, a drug that is widely prescribed for the treatment of high cholesterol, can correct excess hippocampal protein synthesis in the mouse model of FXS and can prevent one of the robust functional consequences of increased protein synthesis in FXS, epileptogenesis. These data suggest that lovastatin is potentially disease modifying and could be a viable prophylactic treatment for epileptogenesis in FXS.

引用

页码：243 / 250

页数：8

共 34 条

[1] The mGIuR theory of fragile X mental retardation [J].

Bear, MF ;

Huber, KM ;

Warren, ST .

TRENDS IN NEUROSCIENCES, 2004, 27 (07) :370-377

[2]

Berry-Kravis E, 2002, DEV MED CHILD NEUROL, V44, P724

[3] The Pathophysiology of Fragile X (and What It Teaches Us about Synapses) [J].

Bhakar, Asha L. ;

Dolen, Gul ;

Bear, Mark F. .

ANNUAL REVIEW OF NEUROSCIENCE, VOL 35, 2012, 35 :417-443

[4] Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment [J].

Choi, Catherine H. ;

Schoenfeld, Brian P. ;

Bell, Aaron J. ;

Hinchey, Paul ;

Kollaros, Maria ;

Gertner, Michael J. ;

Woo, Newton H. ;

Tranfaglia, Michael R. ;

Bear, Mark F. ;

Zukin, R. Suzanne ;

McDonald, Thomas V. ;

Jongens, Thomas A. ;

McBride, Sean M. J. .

BRAIN RESEARCH, 2011, 1380 :106-119

[5] Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model [J].

Chuang, SC ;

Zhao, WF ;

Bauchwitz, R ;

Yan, QJ ;

Bianchi, R ;

Wong, RKS .

JOURNAL OF NEUROSCIENCE, 2005, 25 (35) :8048-8055

[6] Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction [J].

Gegg, ME ;

Harry, R ;

Hankey, D ;

Zambarakji, H ;

Pryce, G ;

Baker, D ;

Adamson, P ;

Calder, V ;

Greenwood, J .

JOURNAL OF IMMUNOLOGY, 2005, 174 (04) :2327-2335

[7] REGULATION OF THE MEVALONATE PATHWAY [J].

GOLDSTEIN, JL ;

BROWN, MS .

NATURE, 1990, 343 (6257) :425-430

[8] Altered Neocortical Rhythmic Activity States in Fmr1 KO Mice Are Due to Enhanced mGluR5 Signaling and Involve Changes in Excitatory Circuitry [J].

Hays, Seth A. ;

Huber, Kimberly M. ;

Gibson, Jay R. .

JOURNAL OF NEUROSCIENCE, 2011, 31 (40) :14223-14234

[9] Altered synaptic plasticity in a mouse model of fragile X mental retardation [J].

Huber, KM ;

Gallagher, SM ;

Warren, ST ;

Bear, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (11) :7746-7750

[10]

Kanner L, 1943, NERV CHILD, V2, P217

← 1 2 3 4 →